Maria Beatriz Madureira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Beatriz Madureira has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Panis
Universidade Estadual do Oeste do Paraná
1 shared publication - Ellen Mayara Souza Cruz
Laboratory of Immunoparasitology of Neglected Diseases and Cancer, Department of Immunology, Parasitology and General Pathology, Center of Biological Sciences, State University of Londrina - UEL, Rodovia Celso Garcia Cid Campus, Post Box 10.011, Londrina, PR, 86057-970, Brazil.
1 shared publication - Fabricio Seidy Ribeiro Inoue
Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina, Londrina 86057-970, Brazil
1 shared publication - Fábio Rodrigues Ferreira Seiva
Department of Chemical and Biological Sciences, Institute of Biosciences, Sao Paulo State University, Botucatu, SP, Brazil
1 shared publication - Juliana Maria Bitencourt de Morais Valentim
Laboratory of Tumor Biology, Western Paraná State University, Francisco Beltrão 85605-010, Parana, Brazil
1 shared publication - Manoela Daniele Gonçalves
Laboratory of Biotransformation and Phytochemical, State University of Londrina, Londrina 86057-970, Brazil
1 shared publication
Latest Publications
- Open Access
- 27 February 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (3) , 586
Naringenin and Hesperidin as Promising Alternatives for Prevention and Co-Adjuvant Therapy for Breast Cancer
Citrus (genus Citrus L.) fruits are essential sources of bioactive compounds with antioxidant properties, such as flavonoids. These polyphenolic compounds are divided into subclasses, in which flavanones are the most prominent. Among them, naringenin and hesperidin are emerging compounds with anticancer potential, especially for breast cancer (BC). Several mechanisms have been proposed, including the modulation of epigenetics, estrogen signaling, induction of cell death via regulation of apoptotic signaling pathways, and inhibition of tumor invasion and metastasis. However, this information is sparse in the literature and needs to be brought together to provide an overview of how naringenin and hesperidin can serve as therapeutic tools for drug development and as a successful co-adjuvant strategy against BC. This review detailed such mechanisms in this context and highlighted how naringenin and hesperidin could interfere in BC carcinogenesis and be helpful as potential alternative therapeutic sources for breast cancer treatment.
- 27 February 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (3) , 586
Open AccessNaringenin and Hesperidin as Promising Alternatives for Prevention and Co-Adjuvant Therapy for Breast Cancer
Citrus (genus Citrus L.) fruits are essential sources of bioactive compounds with antioxidant properties, such as flavonoids. These polyphenolic compounds are divided into subclasses, in which flavanones are the most prominent. Among them, naringenin and hesperidin are emerging compounds with anticancer potential, especially for breast cancer (BC). Several mechanisms have been proposed, including the modulation of epigenetics, estrogen signaling, induction of cell death via regulation of apoptotic signaling pathways, and inhibition of tumor invasion and metastasis. However, this information is sparse in the literature and needs to be brought together to provide an overview of how naringenin and hesperidin can serve as therapeutic tools for drug development and as a successful co-adjuvant strategy against BC. This review detailed such mechanisms in this context and highlighted how naringenin and hesperidin could interfere in BC carcinogenesis and be helpful as potential alternative therapeutic sources for breast cancer treatment.